お知らせ :東京証券取引所JASDAQスタンダード市場への新規上場に関するお知らせ

株式会社グローバルインフォメーション
表紙
市場調査レポート
商品コード
979731

世界のヒトインスリンの市場予測・競合動向・成長機会 (~2025年):適応症・ブランド・投与経路・タイプ・作用発現時間・製品・地域別

Global Human Insulin Market, By Indication, By Brand, By Route of Administration, By Type, By Onset Time, By Products, By Region, Forecast & Opportunities, 2025

出版日: | 発行: TechSci Research | ページ情報: 英文 311 Pages | 納期: お問合せ

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=104.84円

こちらのレポートには、数時間(ご購入金額の10%)分のアナリストへの質問/追加調査サービスが含まれております。

世界のヒトインスリンの市場予測・競合動向・成長機会 (~2025年):適応症・ブランド・投与経路・タイプ・作用発現時間・製品・地域別
出版日: 2021年01月01日
発行: TechSci Research
ページ情報: 英文 311 Pages
納期: お問合せ
  • 全表示
  • 概要
  • 図表
  • 目次
概要

世界のヒトインスリンの市場規模は2019年の269億1000万米ドルから、予測期間中は8.01%のCAGRで成長すると予測されています。高齢者人口の増加、糖尿病患者の増加、肥満の有病率の上昇、ヒトインスリンアナログの需要の増加などの要因が同市場の成長を推進しています。一方で、費用対効果、償還価格、インスリン承認のための厳格な規制要件などの課題が市場のさらなる成長の妨げとなる見通しです。

当レポートでは、世界のヒトインスリンの市場を調査し、市場の定義と概要、新型コロナウイルス感染症 (COVID-19) およびその他の市場影響因子の分析、世界および地域・国別の市場規模および市場シェアの推移・予測、適応症・ブランド・製品・投与経路・タイプ・作用発現時間別・製品など各種区分別の内訳、競合環境、主要企業のプロファイルなどをまとめています。

第1章 製品の概要

第2章 調査手法

第3章 COVID-19の影響

第4章 顧客の声

第5章 エグゼクティブサマリー

第6章 世界市場の展望

  • 市場規模・予測
  • 市場シェア・予測
  • 適応症別
    • I型糖尿病
    • II型糖尿病
  • ブランド別
    • ランタス
    • フムリンR
    • ノボリンR
    • フムリンN
    • Exubera
    • Afrezza
    • ノボリンN
  • 投与経路別
    • 皮下
    • 経鼻
    • 静脈内
    • 経皮
    • 経口
    • その他
  • タイプ別
    • 基礎薬
    • ボーラス投与薬
    • プレミックス薬
    • バイオシミラー薬
    • 従来型
  • 作用発現時間別
    • 速効型
    • 短時間作用型
    • 中程度作用型
    • 長時間作用型
    • 超長時間作用型
    • 事前混合
    • 吸入
  • 製品別
    • インスリンペン
    • インスリンポンプ
    • 注入システム
    • 注射
  • 企業別
  • 地域別
  • 市場魅力指数

第7章 北米市場の展望

  • 市場規模・予測
  • 市場シェア・予測
  • 適応症別
  • ブランド別
  • 投与経路別
  • タイプ別
  • 作用発現時間別
  • 製品別
  • 国別
  • 市場魅力指数
  • 国別分析

第8章 欧州市場の展望

  • 市場規模・予測
  • 市場シェア・予測
  • 適応症別
  • ブランド別
  • 投与経路別
  • タイプ別
  • 作用発現時間別
  • 製品別
  • 国別
  • 市場魅力指数
  • 国別分析

第9章 アジア太平洋市場の展望

  • 市場規模・予測
  • 市場シェア・予測
  • 適応症別
  • ブランド別
  • 投与経路別
  • タイプ別
  • 作用発現時間別
  • 製品別
  • 国別
  • 市場魅力指数
  • 国別分析

第10章 南米市場の展望

  • 市場規模・予測
  • 市場シェア・予測
  • 適応症別
  • ブランド別
  • 投与経路別
  • タイプ別
  • 作用発現時間別
  • 製品別
  • 国別
  • 市場魅力指数
  • 国別分析

第11章 中東・アフリカ市場の展望

  • 市場規模・予測
  • 市場シェア・予測
  • 適応症別
  • ブランド別
  • 投与経路別
  • タイプ別
  • 作用発現時間別
  • 製品別
  • 国別
  • 市場魅力指数
  • 国別分析

第12章 市場力学

  • 促進要因
  • 課題

第13章 市場動向

第14章 競合情勢

  • 競合の見通し
  • 企業プロファイル
    • Novo Nordisk A/S
    • Sanofi S.A.
    • Eli Lilly and Company
    • Biocon Limited
    • Wockhardt Ltd
    • Nektar Therapeutics
    • Mannkind Corporation
    • A-S Medication Solutions
    • Remedyrepack Inc.
    • Torrent Pharmaceuticals
    • Sedico Co.
    • Gan & Lee Pharmaceuticals
    • BioGenomics Ltd
    • Ypsomed AG
    • Becton, Dickinson and Company
    • B. Braun Melsungen AG
    • Baxter International Inc.,
    • Merck & Co., Inc
    • PerkinElmer
    • Pfizer Inc.

第15章 戦略的提言

第16章 当社について・免責事項

図表

List of Figures

  • Figure 1: Global Human Insulin Market Size, By Volume (Million Units), By Value (USD Billion), 2015-2025F
  • Figure 2: Global Human Insulin Market Share, By Indication, By Value, 2015-2025F
  • Figure 3: Global Human Insulin Market Share, By Brand, By Value, 2015-2025F
  • Figure 4: Global Human Insulin Market Share, By Route of Administration, By Value, 2015-2025F
  • Figure 5: Global Human Insulin Market Share, By Type, By Value, 2015-2025F
  • Figure 6: Global Human Insulin Market Share, By Onset Time, By Value, 2015-2025F
  • Figure 7: Global Human Insulin Market Share, By Products, By Value, 2015-2025F
  • Figure 8: Global Human Insulin Market Share, By Company, By Value, 2019
  • Figure 9: Global Human Insulin Market Share, By Region, By Value, 2015-2025F
  • Figure 10: Global Human Insulin Market Share, By Region, By Value, 2015-2025F
  • Figure 11: Global Human Insulin Market Map, By Brand, Market Size (USD Billion) & Growth Rate (%)
  • Figure 12: Global Human Insulin Market Map, By Onset Time, Market Size (USD Billion) & Growth Rate (%)
  • Figure 13: Global Human Insulin Market Map, By Products, Market Size (USD Billion) & Growth Rate (%)
  • Figure 14: Global Human Insulin Market Map, By Region, Market Size (USD Billion) & Growth Rate (%)
  • Figure 15: North America Human Insulin Market Size, By Volume (Million Units), By Value (USD Billion), 2015-2025F
  • Figure 16: North America Human Insulin Market Share, By Indication, By Value, 2015-2025F
  • Figure 17: North America Human Insulin Market Share, By Brand, By Value, 2015-2025F
  • Figure 18: North America Human Insulin Market Share, By Route of Administration, By Value, 2015-2025F
  • Figure 19: North America Human Insulin Market Share, By Type, By Value, 2015-2025F
  • Figure 20: North America Human Insulin Market Share, By Onset Time, By Value, 2015-2025F
  • Figure 21: North America Human Insulin Market Share, By Products, By Value, 2015-2025F
  • Figure 22: North America Human Insulin Market Share, By Country, By Value, 2015-2025F
  • Figure 23: North America Human Insulin Market Map, By Brand, Market Size (USD Billion) & Growth Rate (%)
  • Figure 24: United States Human Insulin Market Size, By Volume (Million Units), By Value (USD Billion), 2015-2025F
  • Figure 25: Total Number of Diabetes patients in United States, By Value (Millions), 2019, 2030, 2045
  • Figure 26: United States Human Insulin Market Share, By Indication, By Value, 2015-2025F
  • Figure 27: United States Human Insulin Market Share, By Brand, By Value, 2015-2025F
  • Figure 28: United States Human Insulin Market Share, By Route of Administration, By Value, 2015-2025F
  • Figure 29: United States Human Insulin Market Share, By Type, By Value, 2015-2025F
  • Figure 30: United States Human Insulin Market Share, By Onset Time, By Value, 2015-2025F
  • Figure 31: United States Human Insulin Market Share, By Products, By Value, 2015-2025F
  • Figure 32: Canada Human Insulin Market Size, By Volume (Million Units), By Value (USD Billion), 2015-2025F
  • Figure 33: Total Number of Diabetes patients in Canada, By Value (1000's), 2010, 2019, 2030, 2045
  • Figure 34: Canada Human Insulin Market Share, By Indication, By Value, 2015-2025F
  • Figure 35: Canada Human Insulin Market Share, By Brand, By Value, 2015-2025F
  • Figure 36: Canada Human Insulin Market Share, By Route of Administration, By Value, 2015-2025F
  • Figure 37: Canada Human Insulin Market Share, By Type, By Value, 2015-2025F
  • Figure 38: Canada Human Insulin Market Share, By Onset Time, By Value, 2015-2025F
  • Figure 39: Canada Human Insulin Market Share, By Products, By Value, 2015-2025F
  • Figure 40: Mexico Human Insulin Market Size, By Volume (Million Units), By Value (USD Billion), 2015-2025F
  • Figure 41: Total Number of Diabetes patients in Mexico, By Value (Millions), 2019, 2030, 2045
  • Figure 42: Mexico Human Insulin Market Share, By Indication, By Value, 2015-2025F
  • Figure 43: Mexico Human Insulin Market Share, By Brand, By Value, 2015-2025F
  • Figure 44: Mexico Human Insulin Market Share, By Route of Administration, By Value, 2015-2025F
  • Figure 45: Mexico Human Insulin Market Share, By Type, By Value, 2015-2025F
  • Figure 46: Mexico Human Insulin Market Share, By Onset Time, By Value, 2015-2025F
  • Figure 47: Mexico Human Insulin Market Share, By Products, By Value, 2015-2025F
  • Figure 48: Europe Human Insulin Market Size, By Volume (Million Units), By Value (USD Billion), 2015-2025F
  • Figure 49: Europe Human Insulin Market Share, By Indication, By Value, 2015-2025F
  • Figure 50: Europe Human Insulin Market Share, By Brand, By Value, 2015-2025F
  • Figure 51: Europe Human Insulin Market Share, By Route of Administration, By Value, 2015-2025F
  • Figure 52: Europe Human Insulin Market Share, By Type, By Value, 2015-2025F
  • Figure 53: Europe Human Insulin Market Share, By Onset Time, By Value, 2015-2025F
  • Figure 54: Europe Human Insulin Market Share, By Products, By Value, 2015-2025F
  • Figure 55: Europe Human Insulin Market Share, By Country, By Value, 2015-2025F
  • Figure 56: Europe Human Insulin Market Map, By Brand, Market Size (USD Billion) & Growth Rate (%)
  • Figure 57: Germany Human Insulin Market Size, By Volume (Million Units), By Value (USD Billion), 2015-2025F
  • Figure 58: Germany undiagnosed and diagnosed diabetes cases, 2019
  • Figure 59: Germany Human Insulin Market Share, By Indication, By Value, 2015-2025F
  • Figure 60: Germany Human Insulin Market Share, By Brand, By Value, 2015-2025F
  • Figure 61: Germany Human Insulin Market Share, By Route of Administration, By Value, 2015-2025F
  • Figure 62: Germany Human Insulin Market Share, By Type, By Value, 2015-2025F
  • Figure 63: Germany Human Insulin Market Share, By Onset Time, By Value, 2015-2025F
  • Figure 64: Germany Human Insulin Market Share, By Products, By Value, 2015-2025F
  • Figure 65: United Kingdom Human Insulin Market Size, By Volume (Million Units), By Value (USD Billion), 2015-2025F
  • Figure 66: Different types of diabetes in United Kingdom, 2019
  • Figure 67: United Kingdom Human Insulin Market Share, By Indication, By Value, 2015-2025F
  • Figure 68: United Kingdom Human Insulin Market Share, By Brand, By Value, 2015-2025F
  • Figure 69: United Kingdom Human Insulin Market Share, By Route of Administration, By Value, 2015-2025F
  • Figure 70: United Kingdom Human Insulin Market Share, By Type, By Value, 2015-2025F
  • Figure 71: United Kingdom Human Insulin Market Share, By Onset Time, By Value, 2015-2025F
  • Figure 72: United Kingdom Human Insulin Market Share, By Products, By Value, 2015-2025F
  • Figure 73: France Human Insulin Market Size, By Volume (Million Units), By Value (USD Billion), 2015-2025F
  • Figure 74: France Healthcare Spending, By Value (USD Per Capita), 2015-2019
  • Figure 75: France Human Insulin Market Share, By Indication, By Value, 2015-2025F
  • Figure 76: France Human Insulin Market Share, By Brand, By Value, 2015-2025F
  • Figure 77: France Human Insulin Market Share, By Route of Administration, By Value, 2015-2025F
  • Figure 78: France Human Insulin Market Share, By Type, By Value, 2015-2025F
  • Figure 79: France Human Insulin Market Share, By Onset Time, By Value, 2015-2025F
  • Figure 80: France Human Insulin Market Share, By Products, By Value, 2015-2025F
  • Figure 81: Italy Human Insulin Market Size, By Volume (Million Units), By Value (USD Billion), 2015-2025F
  • Figure 82: Total Number of Diabetes patients in Italy, By Value (1000's), 2010, 2019, 2030, 2045
  • Figure 83: Italy Human Insulin Market Share, By Indication, By Value, 2015-2025F
  • Figure 84: Italy Human Insulin Market Share, By Brand, By Value, 2015-2025F
  • Figure 85: Italy Human Insulin Market Share, By Route of Administration, By Value, 2015-2025F
  • Figure 86: Italy Human Insulin Market Share, By Type, By Value, 2015-2025F
  • Figure 87: Italy Human Insulin Market Share, By Onset Time, By Value, 2015-2025F
  • Figure 88: Italy Human Insulin Market Share, By Products, By Value, 2015-2025F
  • Figure 89: Spain Human Insulin Market Size, By Volume (Million Units), By Value (USD Billion), 2015-2025F
  • Figure 90: Total Number of Diabetes patients in Spain, By Value (1000's), 2010, 2019, 2030, 2045
  • Figure 91: Spain Human Insulin Market Share, By Indication, By Value, 2015-2025F
  • Figure 92: Spain Human Insulin Market Share, By Brand, By Value, 2015-2025F
  • Figure 93: Spain Human Insulin Market Share, By Route of Administration, By Value, 2015-2025F
  • Figure 94: Spain Human Insulin Market Share, By Type, By Value, 2015-2025F
  • Figure 95: Spain Human Insulin Market Share, By Onset Time, By Value, 2015-2025F
  • Figure 96: Spain Human Insulin Market Share, By Products, By Value, 2015-2025F
  • Figure 97: Russia Human Insulin Market Size, By Volume (Million Units), By Value (USD Billion), 2015-2025F
  • Figure 98: Total Number of Diabetes patients in Russia, By Value (1000's), 2010, 2019, 2030, 2045
  • Figure 99: Russia Human Insulin Market Share, By Indication, By Value, 2015-2025F
  • Figure 100: Russia Human Insulin Market Share, By Brand, By Value, 2015-2025F
  • Figure 101: Russia Human Insulin Market Share, By Route of Administration, By Value, 2015-2025F
  • Figure 102: Russia Human Insulin Market Share, By Type, By Value, 2015-2025F
  • Figure 103: Russia Human Insulin Market Share, By Onset Time, By Value, 2015-2025F
  • Figure 104: Russia Human Insulin Market Share, By Products, By Value, 2015-2025F
  • Figure 105: Asia-Pacific Human Insulin Market Size, By Volume (Million Units), By Value (USD Billion), 2015-2025F
  • Figure 106: Asia-Pacific Human Insulin Market Share, By Indication, By Value, 2015-2025F
  • Figure 107: Asia-Pacific Human Insulin Market Share, By Brand, By Value, 2015-2025F
  • Figure 108: Asia-Pacific Human Insulin Market Share, By Route of Administration, By Value, 2015-2025F
  • Figure 109: Asia-Pacific Human Insulin Market Share, By Type, By Value, 2015-2025F
  • Figure 110: Asia-Pacific Human Insulin Market Share, By Onset Time, By Value, 2015-2025F
  • Figure 111: Asia-Pacific Human Insulin Market Share, By Products, By Value, 2015-2025F
  • Figure 112: Asia-Pacific Human Insulin Market Share, By Country, By Value, 2015-2025F
  • Figure 113: Asia-Pacific Human Insulin Market Map, By Brand, Market Size (USD Billion) & Growth Rate (%)
  • Figure 114: China Human Insulin Market Size, By Volume (Million Units), By Value (USD Billion), 2015-2025F
  • Figure 115: Total Number of Diabetes patients in China, By Value (Millions), 2019, 2030, 2045
  • Figure 116: China Human Insulin Market Share, By Indication, By Value, 2015-2025F
  • Figure 117: China Human Insulin Market Share, By Brand, By Value, 2015-2025F
  • Figure 118: China Human Insulin Market Share, By Route of Administration, By Value, 2015-2025F
  • Figure 119: China Human Insulin Market Share, By Type, By Value, 2015-2025F
  • Figure 120: China Human Insulin Market Share, By Onset Time, By Value, 2015-2025F
  • Figure 121: China Human Insulin Market Share, By Products, By Value, 2015-2025F
  • Figure 122: India Human Insulin Market Size, By Volume (Million Units), By Value (USD Billion), 2015-2025F
  • Figure 123: Total Number of Diabetes patients in India, By Value (Millions), 2019, 2030, 2045
  • Figure 124: India Human Insulin Market Share, By Indication, By Value, 2015-2025F
  • Figure 125: India Human Insulin Market Share, By Brand, By Value, 2015-2025F
  • Figure 126: India Human Insulin Market Share, By Route of Administration, By Value, 2015-2025F
  • Figure 127: India Human Insulin Market Share, By Type, By Value, 2015-2025F
  • Figure 128: India Human Insulin Market Share, By Onset Time, By Value, 2015-2025F
  • Figure 129: India Human Insulin Market Share, By Products, By Value, 2015-2025F
  • Figure 130: Japan Human Insulin Market Size, By Volume (Million Units), By Value (USD Billion), 2015-2025F
  • Figure 131: Japan Total Health Expenditure as a share of GDP, 2015 - 2019
  • Figure 132: Japan Human Insulin Market Share, By Indication, By Value, 2015-2025F
  • Figure 133: Japan Human Insulin Market Share, By Brand, By Value, 2015-2025F
  • Figure 134: Japan Human Insulin Market Share, By Route of Administration, By Value, 2015-2025F
  • Figure 135: Japan Human Insulin Market Share, By Type, By Value, 2015-2025F
  • Figure 136: Japan Human Insulin Market Share, By Onset Time, By Value, 2015-2025F
  • Figure 137: Japan Human Insulin Market Share, By Products, By Value, 2015-2025F
  • Figure 138: South Korea Human Insulin Market Size, By Volume (Million Units), By Value (USD Billion), 2015-2025F
  • Figure 139: Total Number of Diabetes patients in South Korea, By Value (1000's), 2010, 2019, 2030, 2045
  • Figure 140: South Korea Human Insulin Market Share, By Indication, By Value, 2015-2025F
  • Figure 141: South Korea Human Insulin Market Share, By Brand, By Value, 2015-2025F
  • Figure 142: South Korea Human Insulin Market Share, By Route of Administration, By Value, 2015-2025F
  • Figure 143: South Korea Human Insulin Market Share, By Type, By Value, 2015-2025F
  • Figure 144: South Korea Human Insulin Market Share, By Onset Time, By Value, 2015-2025F
  • Figure 145: South Korea Human Insulin Market Share, By Products, By Value, 2015-2025F
  • Figure 146: Australia Human Insulin Market Size, By Volume (Million Units), By Value (USD Billion), 2015-2025F
  • Figure 147: Total Number of Diabetes patients in Australia, By Value (1000's), 2010, 2019, 2030, 2045
  • Figure 148: Australia Human Insulin Market Share, By Indication, By Value, 2015-2025F
  • Figure 149: Australia Human Insulin Market Share, By Brand, By Value, 2015-2025F
  • Figure 150: Australia Human Insulin Market Share, By Route of Administration, By Value, 2015-2025F
  • Figure 151: Australia Human Insulin Market Share, By Type, By Value, 2015-2025F
  • Figure 152: Australia Human Insulin Market Share, By Onset Time, By Value, 2015-2025F
  • Figure 153: Australia Human Insulin Market Share, By Products, By Value, 2015-2025F
  • Figure 154: Singapore Human Insulin Market Size, By Volume (Million Units), By Value (USD Billion), 2015-2025F
  • Figure 155: Total Number of Diabetes patients in Singapore, By Value (1000's), 2010, 2019, 2030, 2045
  • Figure 156: Singapore Human Insulin Market Share, By Indication, By Value, 2015-2025F
  • Figure 157: Singapore Human Insulin Market Share, By Brand, By Value, 2015-2025F
  • Figure 158: Singapore Human Insulin Market Share, By Route of Administration, By Value, 2015-2025F
  • Figure 159: Singapore Human Insulin Market Share, By Type, By Value, 2015-2025F
  • Figure 160: Singapore Human Insulin Market Share, By Onset Time, By Value, 2015-2025F
  • Figure 161: Singapore Human Insulin Market Share, By Products, By Value, 2015-2025F
  • Figure 162: South America Human Insulin Market Size, By Volume (Million Units), By Value (USD Billion), 2015-2025F
  • Figure 163: South America Human Insulin Market Share, By Indication, By Value, 2015-2025F
  • Figure 164: South America Human Insulin Market Share, By Brand, By Value, 2015-2025F
  • Figure 165: South America Human Insulin Market Share, By Route of Administration, By Value, 2015-2025F
  • Figure 166: South America Human Insulin Market Share, By Type, By Value, 2015-2025F
  • Figure 167: South America Human Insulin Market Share, By Onset Time, By Value, 2015-2025F
  • Figure 168: South America Human Insulin Market Share, By Products, By Value, 2015-2025F
  • Figure 169: South America Human Insulin Market Share, By Country, By Value, 2015-2025F
  • Figure 170: South America Human Insulin Market Map, By Brand, Market Size (USD Billion) & Growth Rate (%)
  • Figure 171: Brazil Human Insulin Market Size, By Volume (Million Units), By Value (USD Billion), 2015-2025F
  • Figure 172: Total Number of Diabetes patients in Brazil, By Value (Millions), 2019, 2030, 2045
  • Figure 173: Brazil Human Insulin Market Share, By Indication, By Value, 2015-2025F
  • Figure 174: Brazil Human Insulin Market Share, By Brand, By Value, 2015-2025F
  • Figure 175: Brazil Human Insulin Market Share, By Route of Administration, By Value, 2015-2025F
  • Figure 176: Brazil Human Insulin Market Share, By Type, By Value, 2015-2025F
  • Figure 177: Brazil Human Insulin Market Share, By Onset Time, By Value, 2015-2025F
  • Figure 178: Brazil Human Insulin Market Share, By Products, By Value, 2015-2025F
  • Figure 179: Argentina Human Insulin Market Size, By Volume (Million Units), By Value (USD Billion), 2015-2025F
  • Figure 180: Argentina Health Expenditure (% of GDP), 2015-2019
  • Figure 181: Argentina Human Insulin Market Share, By Indication, By Value, 2015-2025F
  • Figure 182: Argentina Human Insulin Market Share, By Brand, By Value, 2015-2025F
  • Figure 183: Argentina Human Insulin Market Share, By Route of Administration, By Value, 2015-2025F
  • Figure 184: Argentina Human Insulin Market Share, By Type, By Value, 2015-2025F
  • Figure 185: Argentina Human Insulin Market Share, By Onset Time, By Value, 2015-2025F
  • Figure 186: Argentina Human Insulin Market Share, By Products, By Value, 2015-2025F
  • Figure 187: Colombia Human Insulin Market Size, By Volume (Million Units), By Value (USD Billion), 2015-2025F
  • Figure 188: Total Number of Diabetes patients in Colombia, By Value (1000's), 2010, 2019, 2030, 2045
  • Figure 189: Colombia Human Insulin Market Share, By Indication, By Value, 2015-2025F
  • Figure 190: Colombia Human Insulin Market Share, By Brand, By Value, 2015-2025F
  • Figure 191: Colombia Human Insulin Market Share, By Route of Administration, By Value, 2015-2025F
  • Figure 192: Colombia Human Insulin Market Share, By Type, By Value, 2015-2025F
  • Figure 193: Colombia Human Insulin Market Share, By Onset Time, By Value, 2015-2025F
  • Figure 194: Colombia Human Insulin Market Share, By Products, By Value, 2015-2025F
  • Figure 195: Middle East and Africa Human Insulin Market Size, By Volume (Million Units), By Value (USD Billion), 2015-2025F
  • Figure 196: Middle East and Africa Human Insulin Market Share, By Indication, By Value, 2015-2025F
  • Figure 197: Middle East and Africa Human Insulin Market Share, By Brand, By Value, 2015-2025F
  • Figure 198: Middle East and Africa Human Insulin Market Share, By Route of Administration, By Value, 2015-2025F
  • Figure 199: Middle East and Africa Human Insulin Market Share, By Type, By Value, 2015-2025F
  • Figure 200: Middle East and Africa Human Insulin Market Share, By Onset Time, By Value, 2015-2025F
  • Figure 201: Middle East and Africa Human Insulin Market Share, By Products, By Value, 2015-2025F
  • Figure 202: Middle East and Africa Human Insulin Market Share, By Country, By Value, 2015-2025F
  • Figure 203: Middle East & Africa Human Insulin Market Map, By Brand, Market Size (USD Billion) & Growth Rate (%)
  • Figure 204: Saudi Arabia Human Insulin Market Size, By Volume (Million Units), By Value (USD Billion), 2015-2025F
  • Figure 205: Total Number of Diabetes patients in Saudi Arabia, By Value (1000's), 2010, 2019, 2030, 2045
  • Figure 206: Saudi Arabia Human Insulin Market Share, By Indication, By Value, 2015-2025F
  • Figure 207: Saudi Arabia Human Insulin Market Share, By Brand, By Value, 2015-2025F
  • Figure 208: Saudi Arabia Human Insulin Market Share, By Route of Administration, By Value, 2015-2025F
  • Figure 209: Saudi Arabia Human Insulin Market Share, By Type, By Value, 2015-2025F
  • Figure 210: Saudi Arabia Human Insulin Market Share, By Onset Time, By Value, 2015-2025F
  • Figure 211: Saudi Arabia Human Insulin Market Share, By Products, By Value, 2015-2025F
  • Figure 212: South Africa Human Insulin Market Size, By Volume (Million Units), By Value (USD Billion), 2015-2025F
  • Figure 213: Total Number of Diabetes patients in South Africa, By Value (1000's), 2010, 2019, 2030, 2045
  • Figure 214: South Africa Human Insulin Market Share, By Indication, By Value, 2015-2025F
  • Figure 215: South Africa Human Insulin Market Share, By Brand, By Value, 2015-2025F
  • Figure 216: South Africa Human Insulin Market Share, By Route of Administration, By Value, 2015-2025F
  • Figure 217: South Africa Human Insulin Market Share, By Type, By Value, 2015-2025F
  • Figure 218: South Africa Human Insulin Market Share, By Onset Time, By Value, 2015-2025F
  • Figure 219: South Africa Human Insulin Market Share, By Products, By Value, 2015-2025F
  • Figure 220: UAE Human Insulin Market Size, By Volume (Million Units), By Value (USD Billion), 2015-2025F
  • Figure 221: UAE Health Expenditure (% of GDP), 2015-2019
  • Figure 222: UAE Human Insulin Market Share, By Indication, By Value, 2015-2025F
  • Figure 223: UAE Human Insulin Market Share, By Brand, By Value, 2015-2025F
  • Figure 224: UAE Human Insulin Market Share, By Route of Administration, By Value, 2015-2025F
  • Figure 225: UAE Human Insulin Market Share, By Type, By Value, 2015-2025F
  • Figure 226: UAE Human Insulin Market Share, By Onset Time, By Value, 2015-2025F
  • Figure 227: UAE Human Insulin Market Share, By Products, By Value, 2015-2025F
目次
Product Code: 4637

Title:
Global Human Insulin Market, By Indication (Type I Diabetes, Type II Diabetes), By Brand (Lantus, Humulin R, Novolin R, Humulin N, Exubera, Afrezza, Novolin N), By Route of Administration (Subcutaneous, Transdermal, Nasal, Intravenous, Oral and Others), By Type (Basal, Bolus, Pre-mixed, Biosimilar, Traditional), By Onset Time (Rapid Acting, Short-Acting, Intermediate Acting, Long Acting, Pre-Mixed, Inhaled, Ultra-Long Acting), By Products (Insulin Pens, Insulin Pumps, Infusion System, Injections), By Region, Forecast & Opportunities, 2025.

Global human insulin market was valued at USD 26.91 Billion in 2019 is expected to grow at a steady CAGR of 8.01% during the forecast period. Growing geriatric population, increasing diabetic patients, rising prevalence of obesity, and increasing demand for human insulin analogs are contributing to the surging demand for human insulin market, globally. Now a days, diabetes is not only restricted to geriatric population, but it is also common among youth. Also, the technological advancements have eradicated human physical activities leading to obesity and diabetes disorders which is directly influencing the growth of the market. Cost effectiveness, reimbursement prices and strict regulatory requirements for approval of insulin can be considered as a major restraining factor for the market as everyone suffering from diabetes might not be able to afford insulin.

The global human insulin market is segmented on the basis of indication, brand, route of administration, type, onset type, products, and region. Based on indication, market can be bifurcated into type I diabetes and type II diabetes. Type I diabetes is likely to hold the largest market share until 2025 as, human insulin is the most important treatment method for the people suffering from type I diabetes. Based on brand, Lantus segment held the dominant market which is one of the major selling products of Sanofi S.A. As of 2019, subcutaneous segment was the leading segment on the basis of route of administration. This is the most common and preferred route of administration as the insulin is absorbed more quickly. Based on regional analysis, North America dominated the human insulin market in 2019 due to large pool of population suffering from diabetes and presence of leading companies in countries like US and Canada.

Leading players in the global human insulin market include Nektar Therapeutics, MannKind Corporation, Novo Nordisk A/S, Torrent Pharmaceuticals, Inc., Eli Lilly and Company, A-S Medication Solutions, RemedyRepack Inc., Sedico Co., Pharmaceutical Company, Sanofi S.A., Gan & Lee Pharmaceuticals, BioGenomics Ltd., Pfizer Inc., PerkinElmer, Merck & Co., Inc, Biocon Limited, Wockhardt Ltd., Ypsomed AG, Becton Dickinson and Company, B. Braun Melsungen AG, Baxter International Inc., among others.

Years considered for this report:

  • Historical Years: 2015-2018
  • Base Year: 2019
  • Estimated Year: 2020
  • Forecast Period: 2021-2025

Objective of the Study:

  • To analyze and forecast the market size of global human insulin market.
  • To classify and forecast global human insulin market based on indication, brand, route of administration, type, onset type, products and region.
  • To identify drivers and challenges for global human insulin market.
  • To examine competitive developments such as expansions, new product launches, mergers & acquisitions, etc., in global human insulin market.
  • To conduct pricing analysis for global human insulin market.
  • To identify and analyze the profile of leading players operating in global human insulin market.

TechSci Research performed both primary as well as exhaustive secondary research for this study. Initially, TechSci Research sourced a list of hospitals/clinics across the globe. Subsequently, TechSci Research conducted primary research surveys with the identified companies. While interviewing, the respondents were also enquired about their competitors. Through this technique, TechSci Research could include the hospitals/clinics which could not be identified due to the limitations of secondary research. TechSci Research analyzed the hospitals/clinics and presence of all major players across the globe.

TechSci Research calculated the market size of global human insulin market using a bottom-up approach, wherein data for various end-user segments was recorded and forecast for the future years. TechSci Research sourced these values from the industry experts and company representatives and externally validated through analyzing historical data of these product types and applications for getting an appropriate, overall market size. Various secondary sources such as company websites, news articles, press releases, company annual reports, investor presentations and financial reports were also studied by TechSci Research.

Key Target Audience:

  • Hospitals/clinics, research institutes and other stakeholders
  • Government bodies such as regulating authorities and policy makers
  • Organizations, forums and alliances related to human insulin
  • Market research and consulting firms

The study is useful in providing answers to several critical questions that are important for the industry stakeholders such as hospitals/clinics, end users, etc., besides allowing them in strategizing investments and capitalizing on market opportunities.

Report Scope:

In this report, global human insulin market has been segmented into following categories, in addition to the industry trends which have also been detailed below:

  • Market, By Indication:

Type I Diabetes

Type II Diabetes

  • Market, By Brand:

Lantus

Humulin R

Novolin R

Humulin N

Exubera

Afrezza

Novolin N

  • Market, By Route of Administration:

Subcutaneous

Nasal

Intravenous

Transdermal

Oral

Others

  • Market, By Type:

Basal

Bolus

Pre-mixed

Biosimilar

Traditional

  • Market, By Onset Time:

Rapid acting

Short-acting

Intermediate acting

Long acting

Ultra-long acting

Pre-mixed

Inhaled

  • Market, By Products:

Insulin Pens

Insulin Pumps

Infusion System

Injection

  • Market, By Region:

North America

  • United States
  • Mexico
  • Canada

Europe

  • Germany
  • United Kingdom
  • France
  • Italy
  • Spain
  • Russia

Asia-Pacific

  • China
  • India
  • Japan
  • South Korea
  • Australia
  • Singapore

South America

  • Brazil
  • Argentina
  • Colombia

Middle east & Africa

  • Saudi Arabia
  • South Africa
  • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in global human insulin market.

Available Customizations:

With the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

  • Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

2. Research Methodology

3. Impact of COVID-19 on Global Human Insulin Market

4. Executive Summary

5. Voice of Customer

6. Global Human Insulin Market Outlook

  • 6.1. Market Size & Forecast
    • 6.1.1. By Value & Volume
  • 6.2. Market Share & Forecast
    • 6.2.1. By Indication (Type I Diabetes, Type II Diabetes)
    • 6.2.2. By Brand (Lantus, Humulin R, Novolin R, Humulin N, Exubera, Afrezza, Novolin N)
    • 6.2.3. By Route of administration (Subcutaneous, Nasal, Intravenous, Transdermal, Oral and Others)
    • 6.2.4. By Type (Basal, Bolus, Pre-mixed, Biosimilar, Traditional)
    • 6.2.5. By Onset Time (Rapid Acting, Short-Acting, Intermediate Acting, Long Acting, Ultra-long Acting, Pre-Mixed, Inhaled)
    • 6.2.6. By Products (Insulin Pens, Insulin Pumps, Infusion System, Injection)
    • 6.2.7. By Company (2019)
    • 6.2.8. By Region
  • 6.3. Market Attractiveness Index

7. North America Human Insulin Market Outlook

  • 7.1. Market Size & Forecast
    • 7.1.1. By Value & Volume
  • 7.2. Market Share & Forecast
    • 7.2.1. By Indication
    • 7.2.2. By Brand
    • 7.2.3. By Route of Administration
    • 7.2.4. By Type
    • 7.2.5. By Onset Time
    • 7.2.6. By Products
    • 7.2.7. By Country
  • 7.3. Market Attractiveness Index
  • 7.4. North America: Country Analysis
    • 7.4.1. United States Human Insulin Market Outlook
      • 7.4.1.1. Market Size & Forecast
        • 7.4.1.1.1. By Value
      • 7.4.1.2. Market Share & Forecast
        • 7.4.1.2.1. By Indication
        • 7.4.1.2.2. By Brand
        • 7.4.1.2.3. By Route of Administration
        • 7.4.1.2.4. By Type
        • 7.4.1.2.5. By Onset Time
        • 7.4.1.2.6. By Products
    • 7.4.2. Canada Human Insulin Market Outlook
      • 7.4.2.1. Market Size & Forecast
        • 7.4.2.1.1. By Value
      • 7.4.2.2. Market Share & Forecast
        • 7.4.2.2.1. By Indication
        • 7.4.2.2.2. By Brand
        • 7.4.2.2.3. By Route of Administration
        • 7.4.2.2.4. By Type
        • 7.4.2.2.5. By Onset Time
        • 7.4.2.2.6. By Products
    • 7.4.3. Mexico Human Insulin Market Outlook
      • 7.4.3.1. Market Size & Forecast
        • 7.4.3.1.1. By Value
      • 7.4.3.2. Market Share & Forecast
        • 7.4.3.2.1. By Indication
        • 7.4.3.2.2. By Brand
        • 7.4.3.2.3. By Route of Administration
        • 7.4.3.2.4. By Type
        • 7.4.3.2.5. By Onset Time
        • 7.4.3.2.6. By Products

8. Europe Human Insulin Market Outlook

  • 8.1. Market Size & Forecast
    • 8.1.1. By Value & Volume
  • 8.2. Market Share & Forecast
    • 8.2.1. By Indication
    • 8.2.2. By Brand
    • 8.2.3. By Route of Administration
    • 8.2.4. By Type
    • 8.2.5. By Onset Time
    • 8.2.6. By Products
    • 8.2.7. By Country
  • 8.3. Market Attractiveness Index
  • 8.4. Europe: Country Analysis
    • 8.4.1. Germany Human Insulin Market Outlook
      • 8.4.1.1. Market Size & Forecast
        • 8.4.1.1.1. By Value
      • 8.4.1.2. Market Share & Forecast
        • 8.4.1.2.1. By Indication
        • 8.4.1.2.2. By Brand
        • 8.4.1.2.3. By Route of Administration
        • 8.4.1.2.4. By Type
        • 8.4.1.2.5. By Onset Time
        • 8.4.1.2.6. By Products
    • 8.4.2. United Kingdom Human Insulin Market Outlook
      • 8.4.2.1. Market Size & Forecast
        • 8.4.2.1.1. By Value
      • 8.4.2.2. Market Share & Forecast
        • 8.4.2.2.1. By Indication
        • 8.4.2.2.2. By Brand
        • 8.4.2.2.3. By Route of Administration
        • 8.4.2.2.4. By Type
        • 8.4.2.2.5. By Onset Time
        • 8.4.2.2.6. By Products
    • 8.4.3. France Human Insulin Market Outlook
      • 8.4.3.1. Market Size & Forecast
        • 8.4.3.1.1. By Value
      • 8.4.3.2. Market Share & Forecast
        • 8.4.3.2.1. By Indication
        • 8.4.3.2.2. By Brand
        • 8.4.3.2.3. By Route of Administration
        • 8.4.3.2.4. By Type
        • 8.4.3.2.5. By Onset Time
        • 8.4.3.2.6. By Products
    • 8.4.4. Italy Human Insulin Market Outlook
      • 8.4.4.1. Market Size & Forecast
        • 8.4.4.1.1. By Value
      • 8.4.4.2. Market Share & Forecast
        • 8.4.4.2.1. By Indication
        • 8.4.4.2.2. By Brand
        • 8.4.4.2.3. By Route of Administration
        • 8.4.4.2.4. By Type
        • 8.4.4.2.5. By Onset Time
        • 8.4.4.2.6. By Products
    • 8.4.5. Spain Human Insulin Market Outlook
      • 8.4.5.1. Market Size & Forecast
        • 8.4.5.1.1. By Value
      • 8.4.5.2. Market Share & Forecast
        • 8.4.5.2.1. By Indication
        • 8.4.5.2.2. By Brand
        • 8.4.5.2.3. By Route of Administration
        • 8.4.5.2.4. By Type
        • 8.4.5.2.5. By Onset Time
        • 8.4.5.2.6. By Products
    • 8.4.6. Russia Human Insulin Market Outlook
      • 8.4.6.1. Market Size & Forecast
        • 8.4.6.1.1. By Value
      • 8.4.6.2. Market Share & Forecast
        • 8.4.6.2.1. By Indication
        • 8.4.6.2.2. By Brand
        • 8.4.6.2.3. By Route of Administration
        • 8.4.6.2.4. By Type
        • 8.4.6.2.5. By Onset Time
        • 8.4.6.2.6. By Products

9. Asia-Pacific Human Insulin Market Outlook

  • 9.1. Market Size & Forecast
    • 9.1.1. By Value & Volume
  • 9.2. Market Share & Forecast
    • 9.2.1. By Indication
    • 9.2.2. By Brand
    • 9.2.3. By Route of Administration
    • 9.2.4. By Type
    • 9.2.5. By Onset Time
    • 9.2.6. By Products
    • 9.2.7. By Country
  • 9.3. Market Attractiveness Index
  • 9.4. Asia-Pacific: Country Analysis
    • 9.4.1. China Human Insulin Market Outlook
      • 9.4.1.1. Market Size & Forecast
        • 9.4.1.1.1. By Value
      • 9.4.1.2. Market Share & Forecast
        • 9.4.1.2.1. By Indication
        • 9.4.1.2.2. By Brand
        • 9.4.1.2.3. By Route of Administration
        • 9.4.1.2.4. By Type
        • 9.4.1.2.5. By Onset Time
        • 9.4.1.2.6. By Products
    • 9.4.2. India Human Insulin Market Outlook
      • 9.4.2.1. Market Size & Forecast
        • 9.4.2.1.1. By Value
      • 9.4.2.2. Market Share & Forecast
        • 9.4.2.2.1. By Indication
        • 9.4.2.2.2. By Brand
        • 9.4.2.2.3. By Route of Administration
        • 9.4.2.2.4. By Type
        • 9.4.2.2.5. By Onset Time
        • 9.4.2.2.6. By Products
    • 9.4.3. Japan Human Insulin Market Outlook
      • 9.4.3.1. Market Size & Forecast
        • 9.4.3.1.1. By Value
      • 9.4.3.2. Market Share & Forecast
        • 9.4.3.2.1. By Indication
        • 9.4.3.2.2. By Brand
        • 9.4.3.2.3. By Route of Administration
        • 9.4.3.2.4. By Type
        • 9.4.3.2.5. By Onset Time
        • 9.4.3.2.6. By Products
    • 9.4.4. South Korea Human Insulin Market Outlook
      • 9.4.4.1. Market Size & Forecast
        • 9.4.4.1.1. By Value
      • 9.4.4.2. Market Share & Forecast
        • 9.4.4.2.1. By Indication
        • 9.4.4.2.2. By Brand
        • 9.4.4.2.3. By Route of Administration
        • 9.4.4.2.4. By Type
        • 9.4.4.2.5. By Onset Time
        • 9.4.4.2.6. By Products
    • 9.4.5. Australia Human Insulin Market Outlook
      • 9.4.5.1. Market Size & Forecast
        • 9.4.5.1.1. By Value
      • 9.4.5.2. Market Share & Forecast
        • 9.4.5.2.1. By Indication
        • 9.4.5.2.2. By Brand
        • 9.4.5.2.3. By Route of Administration
        • 9.4.5.2.4. By Type
        • 9.4.5.2.5. By Onset Time
        • 9.4.5.2.6. By Products
    • 9.4.6. Singapore Human Insulin Market Outlook
      • 9.4.6.1. Market Size & Forecast
        • 9.4.6.1.1. By Value
      • 9.4.6.2. Market Share & Forecast
        • 9.4.6.2.1. By Indication
        • 9.4.6.2.2. By Brand
        • 9.4.6.2.3. By Route of Administration
        • 9.4.6.2.4. By Type
        • 9.4.6.2.5. By Onset Time
        • 9.4.6.2.6. By Products

10. South America Human Insulin Market Outlook

  • 10.1. Market Size & Forecast
    • 10.1.1. By Value & Volume
  • 10.2. Market Share & Forecast
    • 10.2.1. By Indication
    • 10.2.2. By Brand
    • 10.2.3. By Route of Administration
    • 10.2.4. By Type
    • 10.2.5. By Onset Time
    • 10.2.6. By Products
    • 10.2.7. By Country
  • 10.3. Market Attractiveness Index
  • 10.4. South America: Country Analysis
    • 10.4.1. Brazil Human Insulin Market Outlook
      • 10.4.1.1. Market Size & Forecast
        • 10.4.1.1.1. By Value
      • 10.4.1.2. Market Share & Forecast
        • 10.4.1.2.1. By Indication
        • 10.4.1.2.2. By Brand
        • 10.4.1.2.3. By Route of Administration
        • 10.4.1.2.4. By Type
        • 10.4.1.2.5. By Onset Time
        • 10.4.1.2.6. By Products
    • 10.4.2. Argentina Human Insulin Market Outlook
      • 10.4.2.1. Market Size & Forecast
        • 10.4.2.1.1. By Value
      • 10.4.2.2. Market Share & Forecast
        • 10.4.2.2.1. By Indication
        • 10.4.2.2.2. By Brand
        • 10.4.2.2.3. By Route of Administration
        • 10.4.2.2.4. By Type
        • 10.4.2.2.5. By Onset Time
        • 10.4.2.2.6. By Products
    • 10.4.3. Colombia Human Insulin Market Outlook
      • 10.4.3.1. Market Size & Forecast
        • 10.4.3.1.1. By Value
      • 10.4.3.2. Market Share & Forecast
        • 10.4.3.2.1. By Indication
        • 10.4.3.2.2. By Brand
        • 10.4.3.2.3. By Route of Administration
        • 10.4.3.2.4. By Type
        • 10.4.3.2.5. By Onset Time
        • 10.4.3.2.6. By Products

11. Middle East and Africa Human Insulin Market Outlook

  • 11.1. Market Size & Forecast
    • 11.1.1. By Value & Volume
  • 11.2. Market Share & Forecast
    • 11.2.1. By Indication
    • 11.2.2. By Brand
    • 11.2.3. By Route of Administration
    • 11.2.4. By Type
    • 11.2.5. By Onset Time
    • 11.2.6. By Products
    • 11.2.7. By Country
  • 11.3. Market Attractiveness Index
  • 11.4. MEA: Country Analysis
    • 11.4.1. Saudi Arabia Human Insulin Market Outlook
      • 11.4.1.1. Market Size & Forecast
        • 11.4.1.1.1. By Value
      • 11.4.1.2. Market Share & Forecast
        • 11.4.1.2.1. By Indication
        • 11.4.1.2.2. By Brand
        • 11.4.1.2.3. By Route of Administration
        • 11.4.1.2.4. By Type
        • 11.4.1.2.5. By Onset Time
        • 11.4.1.2.6. By Products
    • 11.4.2. South Africa Human Insulin Market Outlook
      • 11.4.2.1. Market Size & Forecast
        • 11.4.2.1.1. By Value
      • 11.4.2.2. Market Share & Forecast
        • 11.4.2.2.1. By Indication
        • 11.4.2.2.2. By Brand
        • 11.4.2.2.3. By Route of Administration
        • 11.4.2.2.4. By Type
        • 11.4.2.2.5. By Onset Time
        • 11.4.2.2.6. By Products
    • 11.4.3. UAE Human Insulin Market Outlook
      • 11.4.3.1. Market Size & Forecast
        • 11.4.3.1.1. By Value
      • 11.4.3.2. Market Share & Forecast
        • 11.4.3.2.1. By Indication
        • 11.4.3.2.2. By Brand
        • 11.4.3.2.3. By Route of Administration
        • 11.4.3.2.4. By Type
        • 11.4.3.2.5. By Onset Time
        • 11.4.3.2.6. By Products

12. Market Dynamics

  • 12.1. Drivers
  • 12.2. Challenges

13. Market Trends & Developments

14. Competitive Landscape

  • 14.1. Competition Outlook
  • 14.2. Players Profiled (Leading Companies)
    • 14.2.1. Novo Nordisk A/S
    • 14.2.2. Sanofi S.A.
    • 14.2.3. Eli Lilly and Company
    • 14.2.4. Biocon Limited
    • 14.2.5. Wockhardt Ltd
    • 14.2.6. Nektar Therapeutics
    • 14.2.7. Mannkind Corporation
    • 14.2.8. A-S Medication Solutions
    • 14.2.9. Remedyrepack Inc.
    • 14.2.10. Torrent Pharmaceuticals
    • 14.2.11. Sedico Co.
    • 14.2.12. Gan & Lee Pharmaceuticals
    • 14.2.13. BioGenomics Ltd
    • 14.2.14. Ypsomed AG
    • 14.2.15. Becton, Dickinson and Company
    • 14.2.16. B. Braun Melsungen AG
    • 14.2.17. Baxter International Inc.,
    • 14.2.18. Merck & Co., Inc
    • 14.2.19. PerkinElmer
    • 14.2.20. Pfizer Inc.

15. Strategic Recommendations

16. About Us & Disclaimer

株式会社グローバルインフォメーション
© Copyright 1996-2021, Global Information, Inc. All rights reserved.